Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.
2012
61
LTM Revenue n/a
LTM EBITDA n/a
-$47.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Allakos has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Allakos achieved revenue of n/a and an EBITDA of -$111M.
Allakos expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Allakos valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | n/a | n/a | XXX | XXX | XXX |
Gross Profit | n/a | n/a | XXX | XXX | XXX |
Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
EBITDA | -$190M | -$111M | XXX | XXX | XXX |
EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Profit | -$320M | -$186M | XXX | XXX | XXX |
Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Allakos's stock price is $0.
Allakos has current market cap of $29.0M, and EV of -$47.7M.
See Allakos trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
-$47.7M | $29.0M | XXX | XXX | XXX | XXX | $-1.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Allakos has market cap of $29.0M and EV of -$47.7M.
Allakos's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Allakos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Allakos and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | -$47.7M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | 0.4x | XXX | XXX | XXX |
P/E | -0.3x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAllakos's NTM/LTM revenue growth is n/a
Allakos's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.9M for the same period.
Over next 12 months, Allakos's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Allakos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Allakos and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | -42% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | $1.9M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Allakos acquired XXX companies to date.
Last acquisition by Allakos was XXXXXXXX, XXXXX XXXXX XXXXXX . Allakos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Allakos founded? | Allakos was founded in 2012. |
Where is Allakos headquartered? | Allakos is headquartered in United States of America. |
How many employees does Allakos have? | As of today, Allakos has 61 employees. |
Who is the CEO of Allakos? | Allakos's CEO is Dr. Robert Alexander, PhD. |
Is Allakos publicy listed? | Yes, Allakos is a public company listed on NAS. |
What is the stock symbol of Allakos? | Allakos trades under ALLK ticker. |
When did Allakos go public? | Allakos went public in 2018. |
Who are competitors of Allakos? | Similar companies to Allakos include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Allakos? | Allakos's current market cap is $29.0M |
Is Allakos profitable? | Yes, Allakos is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.